The Challenges of Detecting Weak D Serologically

The FDA hasn't really required them to define how the entity reagents should react with these different weak D and partial D types. So I think that will be coming as well so that eventually we'll be able to do a better job, right? Let's add detecting these. We are encouraging the standard setting committees, the standards for transfusion services and blood, blood banks and the IRLS to take a stronger stand on the genotyping. And again, lots of great information in there, but we have just a couple minutes before we finish.